#1 Clinical Trials Search in Europe

Ck-0045

Recent clinical trials are investigating the potential of CK-0045, an interleukin-22 agonist, as a treatment for type 2 diabetes mellitus (T2DM) and obesity. These studies aim to assess the drug’s efficacy, safety, and tolerability when administered subcutaneously. The trials involve both healthy participants and those with T2DM and obesity, exploring the drug’s effects on blood sugar control, body weight, and other metabolic markers.

Table of Contents

What is CK-0045?

CK-0045 is a new medication currently being studied for its potential to treat obesity and type 2 diabetes mellitus (T2DM). It is described as an interleukin-22 agonist, which means it mimics or enhances the action of a naturally occurring substance in the body called interleukin-22[1][2]. Interleukin-22 is a protein that plays a role in regulating metabolism and inflammation in the body.

How Does CK-0045 Work?

While the exact mechanism of action is not fully described in the available information, CK-0045 is designed to act like interleukin-22 in the body. This action may help improve the body’s ability to regulate blood sugar levels and potentially aid in weight loss. The ongoing clinical trials aim to better understand how CK-0045 affects the body and its effectiveness in treating obesity and type 2 diabetes[2].

What Conditions Does CK-0045 Treat?

Based on the clinical trials information, CK-0045 is being studied to treat two main conditions:

  • Obesity and Overweight: CK-0045 is being investigated for its potential to help reduce body weight in people who are overweight or obese[2].
  • Type 2 Diabetes Mellitus (T2DM): The medication is also being studied for its ability to improve blood sugar control in people with type 2 diabetes[2].

Current Clinical Trials

There are currently two main clinical trials being conducted to study CK-0045:

  1. Phase 1 Study: This initial study is focused on assessing the safety, tolerability, and pharmacokinetics (how the drug moves through the body) of CK-0045. It involves both healthy participants and those with obesity[1].
  2. Phase 2a Study: This more advanced study is investigating the effectiveness, safety, and tolerability of CK-0045 in people who are overweight or obese and have type 2 diabetes[2].

How is CK-0045 Administered?

CK-0045 is administered through subcutaneous injection, which means it is injected just under the skin. In the clinical trials, participants receive weekly injections of either CK-0045 or a placebo (a substance that looks like the medication but contains no active ingredient)[1][2].

Potential Benefits of CK-0045

The ongoing clinical trials are investigating several potential benefits of CK-0045, including:

  • Improved blood sugar control: Researchers are studying whether CK-0045 can help improve blood sugar levels after meals in people with type 2 diabetes[2].
  • Weight loss: The medication is being evaluated for its potential to reduce body weight in people who are overweight or obese[2].
  • Changes in cholesterol and other blood fats: The trials are also looking at how CK-0045 might affect various types of cholesterol and other fats in the blood[2].

Safety and Side Effects

As CK-0045 is still in the clinical trial phase, its full safety profile and potential side effects are not yet fully known. The ongoing studies are carefully monitoring participants for any adverse events (side effects) that may occur during treatment[1][2]. This information will be crucial in determining the overall safety of CK-0045 and identifying any potential risks associated with its use.

It’s important to note that CK-0045 is still an experimental medication and is not currently available for general use. More research is needed to fully understand its effectiveness and safety before it can be considered for approval as a treatment for obesity and type 2 diabetes.

Aspect Details
Drug Name CK-0045
Drug Type Interleukin-22 agonist
Administration Subcutaneous injection
Target Conditions Type 2 Diabetes Mellitus, Obesity
Study Phases Phase 1 and Phase 2a
Primary Outcomes Blood sugar control, Safety, Tolerability
Secondary Outcomes Body weight changes, Lipid profile, HbA1c, Drug concentration in blood
Study Designs Randomized, Double-blind, Placebo-controlled
Study Duration Varies from single dose to 30 weeks

FAQ

  • What is CK-0045 and how does it work? CK-0045 is an interleukin-22 agonist, which means it mimics the action of interleukin-22 in the body. This drug is being studied for its potential to improve blood sugar control and reduce body weight in people with type 2 diabetes and obesity.
  • How is CK-0045 administered in these clinical trials? In these trials, CK-0045 is administered subcutaneously (under the skin) as an injection. The frequency of administration varies depending on the study, with some participants receiving weekly doses and others receiving single or multiple doses over several weeks.
  • What are the main goals of these clinical trials? The main goals are to assess the safety and tolerability of CK-0045, evaluate its effects on blood sugar control after meals, measure changes in body weight, and determine the drug's concentration in the blood over time.
  • Who can participate in these clinical trials? The trials involve different groups of participants. One study includes people with type 2 diabetes and overweight/obesity, while another involves healthy participants and otherwise healthy individuals with obesity.
  • How long do these clinical trials last? The duration varies between trials. One study lasts about 30 weeks, including 16 weeks of treatment and 8 weeks of follow-up. Another study ranges from a single dose to multiple doses over 6 weeks, with follow-up lasting up to 8 weeks after the last dose.

Ongoing Clinical Trials on Ck-0045

  • Study on CK-0045 for Patients with Type 2 Diabetes and Obesity

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Interleukin-22 agonist: A substance that mimics the action of interleukin-22, a protein involved in immune responses and metabolism regulation.
  • Type 2 Diabetes Mellitus (T2DM): A chronic condition that affects the way your body processes blood sugar (glucose), characterized by high blood sugar levels due to insulin resistance or insufficient insulin production.
  • Subcutaneous: Beneath the skin. In these trials, it refers to injections given just under the skin.
  • Placebo: A substance that looks like the real medicine but contains no active drug. It's used to compare the effects of the actual drug in clinical trials.
  • HbA1c: Also known as glycated hemoglobin, it's a blood test that shows average blood sugar levels over the past 2-3 months.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Area under the curve (AUC): A measurement used to determine the total exposure to a drug over time.
  • Ctrough: The lowest concentration of a drug in the blood, usually just before the next dose is administered.
  • Lipid profile: A blood test that measures different types of fats in your blood, including total cholesterol, HDL, LDL, and triglycerides.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.

References

  1. https://clinicaltrials.gov/study/NCT05712876
  2. https://clinicaltrials.gov/study/NCT06611930